APLS Apellis Pharmaceuticals Loading...

From BIIB earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:30
Jul 29 ◎
Alisha Alaimo President of North America, Biogen Inc. BIIB Q2 FY26 call
Biogen discusses the acquired Apellis assets (Syfovre, Empaveli) positively, noting strong performance and integration progress.
APLS
HIGH
12:00
Apr 29 ◎
Chris Viebacker President and Chief Executive Officer, Biogen Inc. BIIB Q1 FY26 call
Biogen is confident in Apellis's marketed products (Syfovre, Empaveli) and team, seeing them as a platform to build a nephrology franchise and drive growth.
APLS
HIGH

About APLS Analyst Coverage

Buzzberg tracks APLS (Apellis Pharmaceuticals) across 1 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 2 total trade ideas tracked. Latest voices: Alisha Alaimo, Chris Viebacker.